MINDMAZE THERAPUTCS (RLFTY) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 22, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the filing for FY2023, filed Apr 30, 2024. Each column of the statement tables below links to the filing it was taken from.
MINDMAZE THERAPUTCS (RLFTY) reported $7.5M in revenue for fiscal year 2023, down 2.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
Financial Health Signals
MINDMAZE THERAPUTCS does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
MINDMAZE THERAPUTCS passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) passes.
MINDMAZE THERAPUTCS reported a net loss of $116.8M while operations used $21.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
MINDMAZE THERAPUTCS reported an operating loss of $131.9M against $1.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
MINDMAZE THERAPUTCS generated $7.5M in revenue in fiscal year 2023. This represents a decrease of 2.1% from the prior year.
MINDMAZE THERAPUTCS's EBITDA was -$127.9M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
MINDMAZE THERAPUTCS reported a net loss of $116.8M in fiscal year 2023. The change from the prior year is not meaningful, because that figure was zero or negative.
Cash & Balance Sheet
MINDMAZE THERAPUTCS recorded an outflow of $21.5M in free cash flow in fiscal year 2023, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
MINDMAZE THERAPUTCS held $17.3M in cash against $11K in long-term debt as of fiscal year 2023.
Not reported for fiscal year 2023.
Margins & Returns
MINDMAZE THERAPUTCS's ROE was -188.0% in fiscal year 2023, measuring profit generated per dollar of shareholder equity. This is down 153.1 percentage points from the prior year.
Not reported for fiscal year 2023.
Not shown for fiscal year 2023: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2023: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
MINDMAZE THERAPUTCS invested $1.6M in research and development in fiscal year 2023. This represents a decrease of 88.2% from the prior year.
MINDMAZE THERAPUTCS invested $531K in capex in fiscal year 2023, funding long-term assets and infrastructure. This represents an increase of 1385.9% from the prior year.
Not reported for fiscal year 2023.
RLFTY Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY23Filing | FY22Filing | FY21Filing |
|---|---|---|---|
| Revenue | $7.5M-2.1% | $7.7M+56.7% | $4.9M |
| R&D Expenses | $1.6M-88.2% | $13.4M-35.5% | $20.8M |
| Operating Income | -$131.9Mn/m | -$56.3Mn/m | -$37.5M |
| EBITDA | -$127.9Mn/m | -$52.1Mn/m | -$35.3M |
| Interest Expense | $1.1M-54.5% | $2.5M+72.5% | $1.4M |
| Income Tax | -$16.1Mn/m | -$3.8Mn/m | -$897K |
| Net Income | -$116.8Mn/m | -$55.0Mn/m | -$37.9M |
| EPS (Basic) | -$9.94 | -$5.20 | -$0.01 |
| EPS (Diluted) | -$9.94 | -$5.20 | -$0.01 |
| Diluted Shares (Avg) | 12M | 11M | 3.59B |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, SG&A Expenses.
RLFTY Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY23Filing | FY22Filing | FY21Filing |
|---|---|---|---|
| Total Assets | $90.9M-55.5% | $204.3M-25.7% | $275.1M |
| Current Assets | $21.8M-10.9% | $24.4M-59.3% | $60.1M |
| Cash & Equivalents | $17.3M-16.8% | $20.8M-57.5% | $48.9M |
| Inventory | $663K+169.8% | $246K-42.5% | $428K |
| Accounts Receivable | $1.4M-2.5% | $1.4M+0.4% | $1.4M |
| Goodwill | $64.7M-63.3% | $176.3M-16.2% | $210.3M |
| Total Liabilities | $28.7M-38.8% | $46.9M-38.7% | $76.6M |
| Current Liabilities | $8.2M-29.1% | $11.6M-46.3% | $21.6M |
| Non-Current Liabilities | $20.5M-41.9% | $35.3M-35.8% | $55.1M |
| Long-Term Debt | $11K-38.2% | $17K-96.0% | $433K |
| Total Equity | $62.1M-60.5% | $157.4M-20.7% | $198.5M |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Retained Earnings.
RLFTY Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY23Filing | FY22Filing | FY21Filing |
|---|---|---|---|
| Operating Cash Flow | -$21.0Mn/m | -$26.1Mn/m | -$39.1M |
| Depreciation & Amortization | $3.9M-5.5% | $4.2M+87.6% | $2.2M |
| Capital Expenditures | $531K+1385.9% | $36K | N/A |
| Free Cash Flow | -$21.5Mn/m | -$26.1M | N/A |
| Investing Cash Flow | $10.3Mn/m | -$8.7Mn/m | -$33.1M |
| Financing Cash Flow | $4.8M-30.6% | $6.9M-90.6% | $74.0M |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
RLFTY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY23Filing | FY22Filing | FY21Filing |
|---|---|---|---|
| Operating Margin | -1751.4% | -731.9% | -763.7% |
| Net Margin | -1551.5% | -714.3% | -772.6% |
| Return on Equity | -188.0%-153.1pp | -34.9%-15.8pp | -19.1% |
| Return on Assets | -128.5%-101.6pp | -26.9%-13.1pp | -13.8% |
| Current Ratio | 2.65+0.5x | 2.11-0.7x | 2.79 |
| Debt-to-Equity | 0.000.0x | 0.000.0x | 0.00 |
| Liabilities-to-Equity | 0.46+0.2x | 0.30-0.1x | 0.39 |
| Asset Turnover | 0.080.0x | 0.040.0x | 0.02 |
| FCF Margin | -285.4% | -339.8% | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| MINDMAZE THERAPUTCS RLFTY | FY2023 | $7.5M | -$116.8M | N/A | $30.2M | — |
| ZIVO BIOSCIENCE INC ZIVO | FY2024 | $157K | N/A | N/A | $36.2M | — |
Where MINDMAZE THERAPUTCS Ranks
Frequently Asked Questions
What is MINDMAZE THERAPUTCS's annual revenue?
MINDMAZE THERAPUTCS (RLFTY) reported $7.5M in total revenue for fiscal year 2023. This represents a -2.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is MINDMAZE THERAPUTCS's revenue growing?
MINDMAZE THERAPUTCS (RLFTY) revenue declined by 2.1% year-over-year, from $7.7M to $7.5M in fiscal year 2023.
Is MINDMAZE THERAPUTCS profitable?
No, MINDMAZE THERAPUTCS (RLFTY) reported a net loss of $116.8M in fiscal year 2023.
What is MINDMAZE THERAPUTCS's EBITDA?
MINDMAZE THERAPUTCS (RLFTY) had EBITDA of -$127.9M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does MINDMAZE THERAPUTCS have?
As of fiscal year 2023, MINDMAZE THERAPUTCS (RLFTY) had $17.3M in cash and equivalents against $11K in long-term debt.
What is MINDMAZE THERAPUTCS's return on equity (ROE)?
MINDMAZE THERAPUTCS (RLFTY) has a return on equity of -188.0% for fiscal year 2023, measuring how efficiently the company generates profit from shareholder equity.
What is MINDMAZE THERAPUTCS's free cash flow?
MINDMAZE THERAPUTCS (RLFTY) recorded an outflow of $21.5M in free cash flow during fiscal year 2023. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is MINDMAZE THERAPUTCS's operating cash flow?
MINDMAZE THERAPUTCS (RLFTY) recorded an outflow of $21.0M in operating cash flow during fiscal year 2023, representing cash used by core business activities.
What are MINDMAZE THERAPUTCS's total assets?
MINDMAZE THERAPUTCS (RLFTY) had $90.9M in total assets as of fiscal year 2023, including both current and long-term assets.
What are MINDMAZE THERAPUTCS's capital expenditures?
MINDMAZE THERAPUTCS (RLFTY) invested $531K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.
How much does MINDMAZE THERAPUTCS spend on research and development?
MINDMAZE THERAPUTCS (RLFTY) invested $1.6M in research and development during fiscal year 2023.
What is MINDMAZE THERAPUTCS's current ratio?
MINDMAZE THERAPUTCS (RLFTY) had a current ratio of 2.65 as of fiscal year 2023, which is generally considered healthy.
What is MINDMAZE THERAPUTCS's debt-to-equity ratio?
MINDMAZE THERAPUTCS (RLFTY) had a debt-to-equity ratio of 0.00 as of fiscal year 2023. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is MINDMAZE THERAPUTCS's liabilities-to-equity ratio?
MINDMAZE THERAPUTCS (RLFTY) had a liabilities-to-equity ratio of 0.46 as of fiscal year 2023, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is MINDMAZE THERAPUTCS's return on assets (ROA)?
MINDMAZE THERAPUTCS (RLFTY) had a return on assets of -128.5% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
What is MINDMAZE THERAPUTCS's P/E ratio?
MINDMAZE THERAPUTCS (RLFTY) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2023). The market capitalization is $30.2M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is MINDMAZE THERAPUTCS's price-to-sales ratio?
MINDMAZE THERAPUTCS (RLFTY) trades at 4.0x sales, its market capitalization divided by $7.5M revenue, FY2023. The market capitalization is $30.2M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is MINDMAZE THERAPUTCS's Piotroski F-Score?
MINDMAZE THERAPUTCS (RLFTY) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are MINDMAZE THERAPUTCS's earnings high quality?
MINDMAZE THERAPUTCS (RLFTY) reported a net loss of $116.8M while operations used $21.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can MINDMAZE THERAPUTCS cover its interest payments?
MINDMAZE THERAPUTCS (RLFTY) reported an operating loss of $131.9M against $1.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.